Figure 1
The production of a a recombined bacterium using a gene from a foreign donor and the synthesis of protein encoded by the recombinant DNA molecule.
The genes used in DNA technology are commonly obtained from host cells or organisms calledgene libraries.A gene library is a collection of cells identified as harboring a specific gene. For example,E. colicells can be stored with the genes for human insulin in their chromosomes.
Pharmaceutical products.Gene defects in humans can lead to deficiencies in proteins such as insulin, human growth hormone, and Factor VIII. These protein deficiencies may lead to problems such as diabetes, dwarfism, and impaired blood clotting, respectively. Missing proteins can now be replaced by proteins manufactured through biotechnology. Forinsulinproduction, two protein chains are encoded by separate genes in plasmids inserted into bacteria. The protein chains are then chemically joined to form the final insulin product.Human growth hormoneis also produced within bacteria, but special techniques are used because the bacteria do not usually produce human proteins. Therapeutic proteins produced by biotechnology include a clot-dissolving protein calledtissue plasminogen activator (TPA)andinterferon.This antiviral protein is produced withinE. colicells. Interferon is currently used against certain types of cancers and for certain skin conditions.
Vaccinesrepresent another application of recombinant DNA technology. For instance, the hepatitis B vaccine now in use is composed of viral protein manufactured by yeast cells, which have been recombined with viral genes. The vaccine is safe because it contains no viral particles. Experimental vaccines against AIDS are being produced in the same way.
Diagnostic testing.Recombinant DNA and biotechnology have opened a new era of diagnostic testing and have made detecting many genetic diseases possible. The basic tool of DNA analyses is a fragment of DNA called the DNA probe. ADNA probeis a relatively small, single-stranded fragment of DNA that recognizes and binds to a complementary section of DNA in a complex mixture of DNA molecules. The probe mingles with the mixture of DNA and unites with the target DNA much like a left hand unites with the right. Once the probe unites with its target, it emits a signal such as radioactivity to indicate that a reaction has occurred.
To work effectively, a sufficiently large amount of target DNA must be available. To increase the amount of available DNA, a process called thepolymerase chain reaction (PCR)is used. In a highly automated machine, the target DNA is combined with enzymes, nucleotides, and a primer DNA. In geometric fashion, the enzymes synthesize copies of the target DNA, so that in a few hours billions of molecules of DNA exist where only a few were before.
Using DNA probes and PCR, scientists are now able to detect the DNA associated with HIV (and AIDS), Lyme disease, and genetic diseases such as cystic fibrosis, muscular dystrophy, Huntington's disease, and fragile X syndrome.
Gene therapy. Gene therapyis a recombinant DNA process in which cells are taken from the patient, altered by adding genes, and replaced in the patient, where the genes provide the genetic codes for proteins the patient is lacking.
In the early 1990s, gene therapy was used to correct a deficiency of the enzymeadenosine deaminase (ADA).Blood cells called lymphocytes were removed from the bone marrow of two children; then genes for ADA production were inserted into the cells using viruses as vectors. Finally, the cells were reinfused to the bodies of the two children. Once established in the bodies, the gene-altered cells began synthesizing the enzyme ADA and alleviated the deficiency.
Gene therapy has also been performed with patients withmelanoma(a virulent skin cancer). In this case, lymphocytes that normally attack tumors are isolated in the patients and treated with genes for an anticancer protein calledtumor necrosis factor.The genealtered lymphocytes are then reinfused to the patients, where they produce the new protein which helps destroy cancer cells. Approximately 2000 single-gene defects are believed to exist, and patients with these defects may be candidates for gene therapy.
DNA fingerprinting.The use of DNA probes and the development of retrieval techniques have made it possible to match DNA molecules to one another for identification purposes. This process has been used in a forensic procedure calledDNA fingerprinting.
The use of DNA fingerprinting depends upon the presence of repeating base sequences that exist in the human genome. The repeating sequences are calledrestriction fragment length polymorphisms (RFLPs).As the pattern of RFLPs is unique for every individual, it can be used as a molecular fingerprint. To perform DNA fingerprinting, DNA is obtained from an individual's blood cells, hair fibers, skin fragments, or other tissue. The DNA is extracted from the cells and digested with enzymes. The resulting fragments are separated by a process called electrophoresis. These separated DNA fragments are tested for characteristic RFLPs using DNA probes. A statistical evaluation enables the forensic pathologist to compare a suspect's DNA with the DNA recovered at a crime scene and to assert with a degree of certainty (usually 99 percent) that the suspect was at the crime scene.
DNA and agriculture.Although plants are more difficult to work with than bacteria, gene insertions can be made into single plant cells, and the cells can then be cultivated to form a mature plant. The major method for inserting genes is through the plasmids of a bacterium calledAgrobacterium tumefaciens. This bacterium invades plant cells, and its plasmids insert into plant chromosomes carrying the genes for tumor induction. Scientists remove the tumor-inducing genes and obtain a plasmid that unites with the plant cell without causing any harm.
Recombinant DNA and biotechnology have been used to increase the efficiency of plant growth by increasing the efficiency of the plant's ability to fix nitrogen. Scientists have obtained the genes for nitrogen fixation from bacteria and have incorporated those genes into plant cells. By obtaining nitrogen directly from the atmosphere, the plants can synthesize their own proteins without intervention of bacteria as normally needed.
DNA technology has also been used to increase plant resistance to disease. The genes for an insecticide have been obtained from the bacteriumBacillus thuringiensisand inserted into plants to allow them to resist caterpillars and other pests. In addition, plants have been reengineered to produce the capsid protein that encloses viruses. These proteins lend resistance to the plants against viral disease.
The human genome. One of the most ambitious scientific endeavors of the twentieth century was the effort to sequence the nitrogenous bases in thehuman genome. Begun in 1990 and completed in 2003, the effort encompassed 13 years of work at a cost of approximately $3 billion. Knowing the content of the human genome is helping researchers devise new diagnostics and treatments for genetic diseases and will also be of value to developmental biologists, evolutionary biologists, and comparative biologists.
In addition to learning the genome of humans, the project has also studied numerous bacteria. By 1995, the genomes of two bacteria had been completely deciphered (Haemophilus influenzaeandMycoplasma genitalium), and by 1996, the genome of the yeastSaccharomyces cerevisiaewas known. The Human Genome Project is one of colossal magnitude that will have an impact on many branches of science for decades to come. The project remains the crowning achievement of DNA research in the twentieth century and the bedrock for research in the twenty-first.
Excerpt from:
Recombinant DNA and Biotechnology - CliffsNotes
- Opinion: Canada should invest in itself instead of subsidizing foreign biotechnology companies - The Globe and Mail - April 14th, 2025
- National Commission Outlines Six Ways to Turbocharge U.S. Biotech Innovation Against the Threat from China - Genetic Engineering and Biotechnology... - April 14th, 2025
- Cereno Scientific to attend BIO International Convention 2025 - largest and most comprehensive event for biotechnology - TradingView - April 14th, 2025
- The Future of Plant Biotechnology Services: Market Expected to Reach USD 42.07 Billion by 2032 with 12.8% CAGR - openPR.com - April 14th, 2025
- Understanding the National Security Commission on Emerging Biotechnology Report - CSIS | Center for Strategic and International Studies - April 14th, 2025
- Congressional commission urges $15B, more action to maintain US biotech advantage over China - Fierce Biotech - April 14th, 2025
- Novonesis Poised to Accelerate National Security Commission Priorities on Biotechnology - PR Newswire - April 14th, 2025
- Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky - PR Newswire - April 14th, 2025
- The Future of Mining with AI and Biotechnology Solutions - MSN - April 14th, 2025
- Padilla, Congressional Biotech Commission Introduce Bipartisan Bill to Bolster U.S. Biotechnology Innovation and Economy - Senator Alex Padilla (.gov) - April 14th, 2025
- US commission says $15B biotech investment is needed to maintain dominance over China - FirstWord Pharma - April 14th, 2025
- Senator Young Warns of Biotechnology Competition with China - WIBC - April 14th, 2025
- Research shows need for better mpox protection in HIV-positive patients - The Pharma Letter - April 5th, 2025
- Marine Biotechnology Market to Reach $10.37 Bn by 2032 with 6.2% CAGR - openPR.com - April 5th, 2025
- Robbins LLP Reminds SANA Investors with Large Losses to Contact the Firm for Information About the Securities Fraud Class Action Against Sana... - April 5th, 2025
- Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class... - April 5th, 2025
- Tech Trends 2030: How AI, Quantum Computing, and Biotechnology Will Shape the Future - Analytics Insight - February 24th, 2025
- The Security Implications of Developments in Biotechnology - International Institute for Strategic Studies - February 24th, 2025
- Biotechnology Permits and Notifications - USDA APHIS - February 24th, 2025
- Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage - Nature.com - February 24th, 2025
- Internal cap-initiated translation for efficient protein production from circular mRNA - Nature.com - February 24th, 2025
- MIT class takes students on a grand tour of the interdisciplinary world of biotech - MIT News - February 24th, 2025
- BioTech Breakthrough Awards BostonGene With Cancer Immunology Solution of the Year - Business Wire - February 24th, 2025
- Biodiversity to Bioeconomy - PIB - February 24th, 2025
- Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment... - February 24th, 2025
- Biofach 2025: Biosan Biotechnology CEO talks popular mushroom blends and wellness benefits - Nutrition Insight - February 24th, 2025
- Pushing the boundaries of biotechnology - UC Santa Cruz - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims & More: Daily Recap (1/26/25) - WDW News Today - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims in EPCOT - WDW News Today - January 27th, 2025
- Biotechnology led to dramatic innovations in agriculture and human health in 2024 - Genetic Literacy Project - January 27th, 2025
- Cultured algae and biotechnology are ingredients to the 'Gelato of the future' - STIRworld - January 27th, 2025
- New U.S. Export Controls Seek to Prevent China From Weaponizing Biotech - Foundation for Defense of Democracies - January 27th, 2025
- Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next? - Nature.com - January 27th, 2025
- Nuevocor Welcomes Andreas Wallnfer as Chairman of the Board of Directors - Kilgore News Herald - January 27th, 2025
- Creating and sustaining university biotech spin-outs - PMLiVE - January 27th, 2025
- IMTECH celebrates 41st foundation day with focus on BioE3 policy and biotechnology innovations - The Times of India - January 27th, 2025
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024